The CDCM bridges the divide between laboratory discovery and translation to patients in clinical trials
What is CDCM?
The Center for Definitive and Curative Medicine (CDCM) is a joint initiative of the Stanford University School of Medicine, Stanford Health Care and Stanford Children’s Health. It is co-directed by Drs. Maria Grazia Roncarolo, Anthony Oro, and Matthew Porteus.
The CDCM provides the know-how, organizational and physical infrastructure to support investigator-initiated clinical translational studies on cell and gene therapy (CGT) from initial discovery through completion of clinical proof-of-concept trials. Stanford Medicine’s clinical enterprise provides an exemplary clinical environment in which to deploy cures. The CDCM will support the development of life-changing and curative treatments for patients who come to Stanford to receive the highest level of care.
Why Stanford University?
A number of distinguishing features make Stanford particularly well-positioned to succeed
Pre-eminent, highly-funded cell and gene therapy program
Significant investment in translational infrastructure on campus
Newly built state-of-the-art GMP facility
Excellence in clinical care and access to patient populations
IND Clearance Received for Sickle Cell Disease Gene Editing Clinical Trial
December 14, 2020
FDA Investigational New Drug (IND) clearance has been received to launch a phase I/II clinical trial of gene correction for sickle cell disease.
California Votes Yes on Proposition 14: California Stem Cell Research, Treatments and Cures Initiative of 2020
November 13, 2020
California voters vote Yes on Prop 14! This proposition provides needed funding to continue investing in the research and discovery of stem cell treatments and cures for chronic illnesses and conditions.
Dr. Porteus' article featured in a Nature Communications Editors’ Highlights webpage
May 18, 2020
The editors at Nature Communications have put together an Editors’ Highlights webpage of recent research on Therapeutics and have chosen to feature Dr. Porteus' article, entitled “Cas9-AAV6-Engineered Human Mesenchymal Stromal Cells Improved Cutaneous Wound Healing in Diabetic Mice”.